^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Excerpt:
Each mutation was associated with worse DFS compared with KRAS/BRAF-wild type (all HR point estimates >1). Five of the six KRAS codon 12 mutations (c.34G>A [p.G12D], c.35G>T [p.G12V], c.34G>T [p.G12C], c.35G>C [p.G12A], c.34G>C [p.G12R]) demonstrated a statistically significant association with worse DFS in univariate and multivariate analysis.
DOI:
10.1158/1078-0432.CCR-13-3140
Source:
Title:
Study of JDQ443 , in combination with trametinib or ribociclib or cetuximab, in advanced cancer with a specific mutation (changes in a gene) called KRAS G12C
Excerpt:
...Dose Escalation:•Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.Phase II:•Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy•Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.All patients:•ECOG performance status of 0 or 1.•Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution’s guidelines.`...
Trial ID:
